Research results of autologous stem cell transplant for b cell lymphoma relapse at bach mai hospital
Main Article Content
Abstract
High-dose chemotherapy with autologous stem cell transplant for relapse/refactory non-Hodgkin lymphoma is a modern, highly effective treatment. Research was conducted to evaluate treatment results of autologous hematopoetic stem cell transplantation for B cell lymphoma relapse. This is a descriptive case series method of 12 selected patients. The average grafting time for neutrophils and platelets was 10.2 and 13.3 days, and the mean hospital stay was 33.8 days. The rate of complete response was 11/12 patients. Mean progression-free survival and overall survival are 44.4 ± 8.3 months and 56.1 ± 7.1 months. The progression-free survival and overall survival rate at 3 years are 72.7% and 81.8% and at 5 years are 48.5% and 61.4%.
Article Details
Keywords
non Hodgkin lymphoma, autologous stem cell transplantation, Bach Mai hospital
References
2. B. Coiffier, P. Feugier, N. Mounier et al. Long-term results of the GELA study comparing R-CHOP and CHOP chemotherapy in older patients with diffuse large B-cell lymphoma show good survival in poor-risk patients. Journal of clinical oncology, 2007. 25 (18_suppl), 8009-8009.
3. A. A. Moccia, F. Hitz, P. Hoskins et al. Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma. Leukemia & lymphoma, 58 (2), 2017. 324-332.
4. Esa Jantunen,Carmen Canals,Alessandro Rambaldi et al. Autologous stem cell transplantation in elderly patients(>60 years) with diffuse large B-cell lymphoma:an analysis based on data in the European Bloodand Marrow Transplantation registry. Haematologica 93: 2008. 1837-1842.
5. N. Mounier, C. Canals, C. Gisselbrecht et al. High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry. Biology of Blood and Marrow Transplantation, 2012, 18 (5), 788-793.
6. Jonh R Krause. WHO Classification of Tumors of Haematopoietic and Lymphoid Tisues. 2009.
7. John P. Greer, Michael et al.. Non-Hodgkin Lymphoma in Adults. Wintrobes clinical hematology 12th editition, 2009. 2145-2194.
8. N. Harris, E. Jaffe, J. Diebold et al. Lymphoma classification–from controversy to consensus: the REAL and WHO Classification of lymphoid neoplasms. Annals of oncology, 11, 2000. S3-S10.
9. S. Li, Z. Wang, L. Lin et al. BCL6 rearrangement indicates poor prognosis in diffuse large B-cell lymphoma patients: a meta-analysis of cohort studies. Journal of Cancer, 2019. 10 (2), 530.
10. Mikhail G. Kolonin, paul J.Simmons et al. Stem Cell Mobilization: Methods and Protocols, Methods in Molecular Biology, Springer Science & Business Media, USA, 2012. 904, 37-47.
11. Bạch Quốc Khánh. Nghiên cứu hiệu quả của ghép tế bào tự thân điều trị bệnh nhân Đa u tủy xương và U lympho ác tính không Hodgkin”, Luận văn tiến sỹ y học, Đại học y Hà Nội. 2013.
12. I. Berber, M. A. Erkurt, I. Nizam et al. Can BuCyE conditioning regimen be an alternative treatment to BEAM at autologous transplantation in malignant lymphoma patients?: a single center experience. International journal of clinical and experimental medicine, 2015, 8 (9), 16308.
13. J. Sapelli, J. Schmidt Filho, G. M. M. Vieira et al. Bucye Can Safely Replace BEAM As Conditioning Regimen for Autologous Stem Cell Transplantation for Relapsed Lymphomas. Biology of Blood and Marrow Transplantation, 2020, 26 (3), S152.
14. A. M. Evens, A. Vanderplas, A. S. LaCasce et al. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project. Cancer, 119 (20), 2013, 3662-3671.